



Q4 and Full Year 2024 Earnings Presentation

February 24, 2025

Forward-looking statements and non-GAAP information

This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our Marseille, France operations; 2025 and 2026 financial and operating results; our strategic focuses for the business; and our intentions with respect to our tests and products, for use in diagnosing and treating diseases, in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would”, “will,” “enable,” “positioned,” “offers,” “designed,” “look forward,” “vision,” “strategic,” “on track,” “progress,” “outlook,” “guidance,” “forecast,” “target,” “goal” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics acquisition, integration of the business and realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine, and other regional conflicts, on European economies and energy supply, as well as our facilities in France; the impact of foreign currency fluctuations, volatile interest rates, inflation, the new U.S. administration and turmoil in the global banking and finance system; the ongoing conflicts in Russia and Ukraine and in the Middle East and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 29, 2024, and our subsequent Quarterly Reports on Form 10-Q, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

This presentation also contains information gathered from market research, estimates and other statistical data made by independent parties and by us relating to addressable market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation contains certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue, non-GAAP net income, non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding (WASO). These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures.



We compute these non-GAAP measures by adjusting the applicable GAAP measure to remove the impact of certain recurring and non-recurring charges and gains and to adjust for the impact of income tax items related to such adjustments to our GAAP financial statements. In particular, we exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HaliuDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HaliuDx intangible assets, stock-based compensation and certain costs related to restructuring from certain of our non-GAAP measures. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from all of our prior-period non-GAAP financial measures, as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts our performance, especially when comparing such results to previous periods or forecasts. We encourage investors to carefully consider its results under GAAP, together with its supplemental non-GAAP information and the reconciliation between these presentations. Reconciliations between our GAAP results and non-GAAP financial measures are presented in the Appendix.

Veracyte, the Veracyte logo, Decipher, C2i Genomics, and Afirma are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.z

Our vision is to
**transform cancer
care for patients
all over the world**



Strong topline growth driven by testing revenue




Testing accounted for ~95% of total revenue in 2024

1. Testing revenue includes cytology revenue of \$2.3 million in the fourth quarter and \$9.4 million for the full year

Durable testing revenue growth driving profitability

Testing Revenue (M)



GAAP Net Income

FY 2024: **\$24M**

Adjusted EBITDA Margin

FY 2024: **20.6%**


Cash and short-term investments balance²

FY 2024: **\$289M**

1. Other includes between \$1.9 million and \$2.5 million per quarter of cytology revenue.
 2. Ending balance of cash, cash equivalents and short-term investments, excluding restricted cash

Growing Decipher

Quarterly Volume



Significant growth across all NCCN localized risk categories in Q4 and 2024




85 clinical studies on clinical utility and validity including 42 biopsy, over a dozen that could inform active surveillance decisions, and 43 RP



20 new publications, abstracts posters and presentations highlighting Decipher, and Decipher GRID, since our last earnings call

Decipher[®]

Market leader in molecular diagnostics for prostate cancer prognosis & prediction



Growth opportunities for Decipher in 2025 driven by our platform



Decipher® Prostate Genomic Classifier



22-Gene Genomic Classifier (GC) (Decipher) is the **only gene expression test** included in v1.2025 NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer¹




Received **approval** of the technical assessment from the Molecular Diagnostic Services Program (**MoIDx**), and secured **New York State Clinical Laboratory Evaluation Program approval (CLEP)** for Decipher's use in patients with metastatic prostate cancer



Training and launch planning are underway for a first half of 2025 **launch of Decipher for use in the metastatic population** with volume contribution expect in the second half of 2025

Growing Afirma

Quarterly Volume



12%

Y/Y Afirma volume growth in 2024



Deeper penetration & sizeable new customers, drove Q4 growth


>80%

Q4 Y/Y revenue growth for Bethesda V/VI nodule testing

Assume **high-single-digit** revenue growth in 2025

Afirma®

Market leader in thyroid molecular diagnostics



Strategic growth drivers to expand the reach of our platform



Continue to **grow** established tests

Decipher

Afirma



Serve more of the patient journey

MRD



Expand geographically

IVD



Solve new cancer challenges


Nasal Swab

Balance growth with financial discipline

Strong topline growth driven by testing revenue


Total Revenue (M)

Q4 Full Year



Testing Revenue (M)¹


Q4 Full Year



Profitable growth driven by our proven platform


GAAP Net Income (Loss)¹

Full Year




Adjusted EBITDA Margin

Full Year



Cash and short-term investments balance²

End of Year



1. In millions
2. Ending balance of cash, cash equivalents and short-term investments, excluding restricted cash, in millions

Veracyte SAS financials

Assumed Quarterly Revenue Trends

- Revenue could be impacted at any time depending on our ability to continue servicing existing customers

Product:

~\$2M

Biopharma and Other:

~\$2M

Assumed Quarterly Cost Structure and Cash Burn

- Cost structure will be impacted if a sale or bankruptcy proceeding are completed

Fixed cost structure of


~\$7M

Net operating losses of

~\$5M

Initiating outlook for 2025

Testing Revenue (M)^{1,2}



14%-16% YOY revenue growth adjusting for ~\$6M of Envisia revenue in 2024

Adjusted EBITDA Margin^{1,2}



100bps improvement compared to 2024 adjusted EBITDA margin of 20.6%

1. The company is unable to provide a quantitative reconciliation of expected adjusted EBITDA as a percentage of revenue to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, that are dependent on various factors, are out of the company's control, or that cannot be reasonably predicted. Such adjustments include, but are not limited to, acquisition related expenses and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled "Forward-looking statements and non-GAAP information" at the beginning of this presentation.

2. Guidance provided as of February 24, 2025

Looking forward

2025

Further penetration and share gains

Decipher for metastatic patients

Afirma and Decipher clinical evidence

NIGHTINGALE enrollment

Outcome of the Veracyte SAS process underway

2026-2028

MIBC MRD Launch in 1H'26

Launch IVD products

Additional MRD platform launches

NIGHTINGALE readout

Enhanced profitability with a goal of 25% adjusted EBITDA¹



veracyte.®

Reconciliation of Non-GAAP Gross Profit and Gross Margin

(Unaudited)
(In thousands of dollars)

Three Months Ended	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024
GAAP cost of testing revenue	\$ 21,827	\$ 24,105	\$ 25,979	\$ 27,920	\$ 29,029	\$ 31,645
Stock-based compensation expense	(382)	(392)	(390)	(497)	(524)	(562)
Acquisition related expenses (1)	-	-	(60)	-	-	-
Other adjustments (2)	-	-	(6)	-	-	-
Non-GAAP cost of testing revenue	\$ 21,445	\$ 23,713	\$ 25,523	\$ 27,423	\$ 28,505	\$ 31,083
GAAP cost of product revenue	\$ 2,436	\$ 1,753	\$ 2,644	\$ 1,874	\$ 1,792	\$ 2,800
Stock-based compensation expense	-	-	(1)	(1)	(1)	(1)
Acquisition related expenses (1)	-	-	-	-	-	-
Other adjustments (2)	-	-	-	-	-	-
Non-GAAP cost of product revenue	\$ 2,436	\$ 1,753	\$ 2,643	\$ 1,873	\$ 1,791	\$ 2,799
GAAP cost of biopharmaceutical and other revenue	\$ 3,347	\$ 3,518	\$ 2,838	\$ 3,812	\$ 3,112	\$ 2,622
Stock-based compensation expense	(120)	(80)	(96)	(106)	(62)	(78)
Acquisition related expenses (1)	-	-	-	-	-	-
Other adjustments (2)	-	-	-	-	-	-
Non-GAAP cost of biopharmaceutical and other revenue	\$ 3,227	\$ 3,438	\$ 2,742	\$ 3,706	\$ 3,050	\$ 2,544
GAAP Gross Profit	\$ 57,687	\$ 64,788	\$ 62,468	\$ 77,913	\$ 79,010	\$ 78,754
GAAP Gross Margin	64.0 %	66.0 %	64.5 %	68.1 %	68.2 %	66.4 %
Amortization of intangible assets	4,811	4,035	2,915	2,909	2,917	2,811
Stock-based compensation expense	502	472	487	604	587	641
Acquisition related expenses (1)	-	-	60	-	-	-
Other adjustments (2)	-	-	6	-	-	-
Non-GAAP Gross Profit	\$ 63,000	\$ 69,295	\$ 65,936	\$ 81,426	\$ 82,514	\$ 82,206
Non-GAAP Gross Margin	69.9 %	70.6 %	68.1 %	71.2 %	71.2 %	69.3 %

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended Mar 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics.
2. For the three months ended Mar 31, 2024, adjustments include expense related to restructuring costs associated with portfolio prioritization.
3. Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding.

Reconciliation of Non-GAAP Gross Profit and Gross Margin

(Unaudited)
(In thousands of dollars)

Twelve Months Ended	Dec 31, 2023	Dec 31, 2024
GAAP cost of testing revenue	\$ 88,913	\$ 114,573
Stock-based compensation expense	(1,441)	(1,973)
Acquisition related expenses (1)	(74)	(60)
Other adjustments (2)	-	(6)
Non-GAAP cost of testing revenue	\$ 87,398	\$ 112,534
GAAP cost of product revenue	\$ 8,666	\$ 9,110
Stock-based compensation expense	-	(4)
Acquisition related expenses (1)	-	-
Other adjustments (2)	-	-
Non-GAAP cost of product revenue	\$ 8,666	\$ 9,106
GAAP cost of biopharmaceutical and other revenue	\$ 15,324	\$ 12,384
Stock-based compensation expense	(417)	(342)
Acquisition related expenses (1)	-	-
Other adjustments (2)	-	-
Non-GAAP cost of biopharmaceutical and other revenue	\$ 14,907	\$ 12,042
GAAP Gross Profit	\$ 229,684	\$ 298,145
GAAP Gross Margin	63.6 %	66.9 %
Amortization of intangible assets	18,464	11,552
Stock-based compensation expense	1,858	2,319
Acquisition related expenses (1)	74	60
Other adjustments (2)	-	6
Non-GAAP Gross Profit	\$ 250,080	\$ 312,082
Non-GAAP Gross Margin	69.3 %	70.0 %

1. Includes transaction-related expenses and post-combination compensation expenses. For the twelve months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the twelve months ended December 31, 2023, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HaliuDx.

2. For the twelve months ended December 31, 2024, adjustments include expense related to restructuring costs associated with portfolio prioritization.

Reconciliation of Non-GAAP Operating Expenses

(Unaudited)

(In thousands of dollars)

Three Months Ended	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024
GAAP research and development	\$ 13,322	\$ 18,673	\$ 15,965	\$ 16,465	\$ 17,574	\$ 19,290
Stock-based compensation expense	(1,135)	(1,495)	(1,763)	(1,895)	(1,957)	(1,896)
Acquisition related expenses (1)	-	-	(420)	23	459	-
Other adjustments (2)	-	-	(278)	2	5	-
Non-GAAP research and development	\$ 12,187	\$ 17,178	\$ 13,504	\$ 14,595	\$ 16,081	\$ 17,394
GAAP sales and marketing	\$ 24,344	\$ 25,260	\$ 23,782	\$ 24,216	\$ 22,612	\$ 24,824
Stock-based compensation expense	(2,521)	(2,498)	(1,093)	(2,142)	(1,790)	(1,872)
Acquisition related expenses (1)	(209)	-	(124)	-	-	-
Other adjustments (2)	-	-	(900)	(194)	7	-
Non-GAAP sales and marketing	\$ 21,614	\$ 22,762	\$ 21,665	\$ 21,880	\$ 20,829	\$ 22,952
GAAP general and administrative	\$ 16,334	\$ 23,795	\$ 26,210	\$ 31,745	\$ 25,742	\$ 26,913
Stock-based compensation expense	(3,174)	(3,142)	(4,676)	(5,213)	(4,413)	(5,220)
Acquisition related expenses (1)	4,790	(2,718)	(3,469)	(1,116)	(349)	(928)
Other adjustments (2)	-	-	(266)	(2,854)	(248)	(3,196)
Non-GAAP general and administrative	\$ 17,950	\$ 17,935	\$ 17,799	\$ 22,562	\$ 20,732	\$ 17,569
GAAP total operating expenses	\$ 89,426	\$ 100,295	\$ 67,124	\$ 73,307	\$ 66,993	\$ 74,579
Amortization of intangible assets	(526)	(528)	(738)	(881)	(880)	(798)
Stock-based compensation expense	(6,830)	(7,135)	(7,532)	(9,250)	(8,160)	(8,988)
Acquisition related expenses (1)	4,581	(2,718)	(4,442)	(1,093)	(75)	(961)
Other adjustments (2)	(34,900)	(32,039)	(1,444)	(3,046)	(236)	(5,917)
Non-GAAP total operating expenses	\$ 51,751	\$ 57,875	\$ 52,968	\$ 59,037	\$ 57,642	\$ 57,915

- Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$1.0 million). For the three months ended Sep 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$0.1 million). For the three months ended Jun 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$1.0 million) and adjustments relating to the remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy (\$0.1 million). For the three months ended Mar 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the three months ended Dec 31, 2023, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$2.6 million) and remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy (\$0.1 million). For the three months ended Sep 30, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HaliuDx.
- For the three months ended December 31, 2024, adjustments primarily include expense related to Veracyte SAS site investment review (\$3.2 million) and expense related to the impairment charge associated with HaliuDx (\$2.7 million). For the three months ended Sep 30, 2024, adjustments primarily include expense related to restructuring costs (\$0.2 million). For the three months ended Jun 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment (\$2.9 million) and with portfolio prioritization (\$0.2 million). For the three months ended Mar 31, 2024, adjustment includes \$1.4 million expense related to restructuring costs associated with portfolio prioritization. For the three months ended Dec 31, 2023, adjustment includes \$32.0 million expense related to the impairment charge associated with HaliuDx. For the three months ended Sep 30, 2023, adjustment includes \$34.9 million related to nCounter license impairment related to our adoption of a multi-platform IVD strategy.
- Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding.

Reconciliation of Non-GAAP Operating Expenses

(Unaudited)
(In thousands of dollars)

Twelve Months Ended	Dec 31, 2023	Dec 31, 2024
GAAP research and development	\$ 57,305	\$ 69,294
Stock-based compensation expense	(5,326)	(7,511)
Acquisition related expenses (1)	-	62
Other adjustments (2)	-	(271)
Non-GAAP research and development	\$ 51,979	\$ 61,574
GAAP sales and marketing	\$ 101,490	\$ 95,434
Stock-based compensation expense	(9,624)	(6,897)
Acquisition related expenses (1)	(1,366)	(124)
Other adjustments (2)	-	(1,087)
Non-GAAP sales and marketing	\$ 90,500	\$ 87,326
GAAP general and administrative	\$ 86,229	\$ 110,610
Stock-based compensation expense	(16,681)	(19,522)
Acquisition related expenses (1)	447	(5,862)
Other adjustments (2)	66	(6,564)
Non-GAAP general and administrative	\$ 70,061	\$ 78,662
GAAP total operating expenses	\$ 315,479	\$ 282,003
Amortization of intangible assets	(2,106)	(3,297)
Stock-based compensation expense	(31,631)	(33,930)
Acquisition related expenses (1)	(919)	(6,571)
Other adjustments (2)	(68,283)	(10,643)
Non-GAAP total operating expenses	\$ 212,540	\$ 227,562

- Includes transaction-related expenses as well as post-combination compensation expenses. For the twelve months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the twelve months ended December 31, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy, post-combination compensation expenses associated with the acquisition of HaliuDx and transaction related expenses associated with the acquisition of C2i Genomics.
- For the twelve months ended December 31, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment and with portfolio prioritization, expense related to Veracyte SAS site investment review and expense related to the impairment charge associated with HaliuDx. For the twelve months ended December 31, 2023, adjustments primarily include \$34.9 million expense related to the impairment charge associated with the nCounter license intangible assets, \$32.0 million expense related to the impairment charge associated with HaliuDx and \$1.3 million related to other impairment charges.

Reconciliation of Adjusted EBITDA

(Unaudited)
(In thousands of dollars)

Three Months Ended	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024
GAAP Net Income (Loss)	\$ (29,618)	\$ (28,293)	\$ (1,864)	\$ 5,734	\$ 15,155	\$ 5,113
GAAP Net Income (Loss) as a % of Revenue	(32.9 %)	(28.8 %)	(1.9 %)	5.0 %	13.1 %	4.3 %
Amortization of intangible assets	5,337	4,563	3,653	3,790	3,797	3,609
Depreciation expense	1,985	1,773	1,937	1,948	2,081	2,643
Stock-based compensation expense	7,332	7,607	8,019	9,854	8,747	9,629
Acquisition related expenses (1)	(4,581)	2,718	4,502	1,093	75	961
Other expense (income), net (2)	(2,620)	(3,399)	(3,262)	(3,052)	(3,366)	(1,967)
Other adjustments (3)	34,900	32,039	1,450	3,046	(853)	7,807
Income tax expense (benefit)	(154)	(2,179)	(44)	1,627	1,693	(1,670)
Adjusted EBITDA	\$ 12,581	\$ 14,829	\$ 14,391	\$ 24,040	\$ 27,329	\$ 26,125
Adjusted EBITDA as a % of Revenue	14.0 %	15.1 %	14.9 %	21.0 %	23.6 %	22.0 %

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$1.0 million). For the three months ended Sep 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$0.1 million). For the three months ended June 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$1.0 million) and adjustments relating to the remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy (\$0.1 million). For the three months ended Mar 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the three months ended Dec 31, 2023, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$2.6 million) and remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy (\$0.1 million). For the three months ended Sep 30, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx.
2. Includes interest income and income related to research tax credits.
3. For the three months ended December 31, 2024, adjustments primarily include the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans (\$1.9 million), expense related to Veracyte SAS site investment review (\$3.2 million) and expense related to the impairment charge associated with HalioDx (\$2.7 million). For the three months ended Sep 30, 2024, adjustments include the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans (\$1.1 million) partially offset by expense related to restructuring costs (\$0.2 million). For the three months ended June 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment (\$2.9 million) and with portfolio prioritization (\$0.2 million). For the three months ended Mar 31, 2024, adjustment includes \$1.4 million expense related to restructuring costs associated with portfolio prioritization. For the three months ended Dec 31, 2023, adjustment includes \$32.0 million expense related to the impairment charge associated with HalioDx. For the three months ended Sep 30, 2023, adjustment includes \$34.9 million related to nCounter license impairment related to our adoption of a multi-platform IVD strategy.
4. Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding.

Reconciliation of Adjusted EBITDA

(Unaudited)
(In thousands of dollars)

Twelve Months Ended	Dec 31, 2023	Dec 31, 2024
GAAP Net Income (Loss)	\$ (74,404)	\$ 24,138
GAAP Net Income (Loss) as a % of Revenue	(20.6 %)	5.4 %
Amortization of intangible assets	20,570	14,849
Depreciation expense	6,618	8,610
Stock-based compensation expense	33,489	36,249
Acquisition related expenses (1)	993	6,631
Other expense (income), net (2)	(7,922)	(11,647)
Other adjustments (3)	68,283	11,450
Income tax expense (benefit)	(2,208)	1,606
Adjusted EBITDA	\$ 45,419	\$ 91,886
Adjusted EBITDA as a % of Revenue	12.6 %	20.6 %

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the twelve months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the twelve months ended December 31, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy, post-combination compensation expenses associated with the acquisition of HalioDx and transaction related expenses associated with the acquisition of C2i Genomics.
2. Includes interest income and income related to research tax credits.
3. For the twelve months ended December 31, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment and with portfolio prioritization, expense related to Veracyte SAS site investment review, expense related to the impairment charge associated with HalioDx and the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans. For the twelve months ended December 31, 2023, adjustments primarily include \$34.9 million expense related to the impairment charge associated with the nCounter license intangible assets, \$32.0 million expense related to the impairment charge associated with HalioDx and \$1.3 million related to other impairment charges.

Reconciliation of Non-GAAP Net Income, EPS and WASO

(Unaudited)
(In thousands of dollars)

Three Months Ended	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024
GAAP Net Income (Loss)	\$ (29,618)	\$ (28,293)	\$ (1,864)	\$ 5,734	\$ 15,155	\$ 5,113
Amortization of intangible assets	5,337	4,563	3,653	3,790	3,797	3,609
Stock-based compensation expense	7,332	7,607	8,019	9,854	8,747	9,629
Acquisition related expenses (1)	(4,581)	2,718	4,502	1,093	75	961
Other adjustments (2)	34,900	32,039	1,450	3,046	(853)	7,807
Tax adjustments (3)	(1,124)	(3,387)	(1,132)	(114)	(933)	1,830
Non-GAAP Net Income	\$ 12,246	\$ 15,247	\$ 14,628	\$ 23,403	\$ 25,988	\$ 28,949
Diluted EPS, GAAP	\$ (0.41)	\$ (0.39)	\$ (0.02)	\$ 0.07	\$ 0.19	\$ 0.06
Amortization of intangible assets	0.07	0.06	0.05	0.05	0.05	0.05
Stock-based compensation expense	0.10	0.10	0.11	0.13	0.11	0.12
Acquisition related expenses (1)	(0.06)	0.04	0.06	0.01	-	0.01
Other adjustments (2)	0.48	0.44	0.02	0.04	(0.01)	0.10
Tax adjustments (3)	(0.02)	(0.05)	(0.02)	-	(0.01)	0.02
Rounding and impact of dilutive shares	0.01	0.01	(0.01)	-	-	-
Diluted EPS, non-GAAP	\$ 0.17	\$ 0.21	\$ 0.19	\$ 0.30	\$ 0.33	\$ 0.36
Diluted WASO, GAAP	72,804,770	73,107,059	74,759,789	77,163,149	78,464,654	79,905,412
Dilutive effect of equity awards (4)	1,326,143	1,117,195	1,117,286	-	-	-
Diluted WASO, non-GAAP	74,130,913	74,224,254	75,877,075	77,163,149	78,464,654	79,905,412

- Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$1.0 million). For the three months ended Sep 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$0.1 million). For the three months ended Jun 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$1.0 million) and adjustments relating to the remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy (\$0.1 million). For the three months ended Mar 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the three months ended Dec 31, 2023, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics (\$2.6 million) and remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy (\$0.1 million). For the three months ended Sep 30, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx.
- For the three months ended December 31, 2024, adjustments primarily include the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans (\$1.9 million), expense related to Veracyte SAS site investment review (\$3.2 million) and expense related to the impairment charge associated with HalioDx (\$2.7 million). For the three months ended Sep 30, 2024, adjustments include the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans (\$1.1 million) partially offset by expense related to restructuring costs (\$0.2 million). For the three months ended Jun 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment (\$2.9 million) and with portfolio prioritization (\$0.2 million). For the three months ended Mar 31, 2024, adjustment includes \$1.4 million expense related to restructuring costs associated with portfolio prioritization. For the three months ended Dec 31, 2023, adjustment includes \$32.0 million expense related to the impairment charge associated with HalioDx. For the three months ended Sep 30, 2023, adjustment includes \$34.9 million related to nCounter license impairment related to our adoption of a multi-platform IVD strategy.
- Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.
- In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method.
- Some figures rounded for reporting purposes. Summed quarters may differ slightly from year-to-date figures presented due to rounding or use of weighted-averages when calculating earnings per share.

Reconciliation of Non-GAAP Net Income, EPS and WASO

(Unaudited)
(In thousands of dollars)

Twelve Months Ended	Dec 31, 2023	Dec 31, 2024
GAAP Net Income (Loss)	\$ (74,404)	\$ 24,138
Amortization of intangible assets	20,570	14,849
Stock-based compensation expense	33,489	36,249
Acquisition related expenses (1)	993	6,631
Other adjustments (2)	68,283	11,450
Tax adjustments (3)	(5,638)	(349)
Non-GAAP Net Income	\$ 43,293	\$ 92,968
Diluted EPS, GAAP	\$ (1.02)	\$ 0.31
Amortization of intangible assets	0.28	0.19
Stock-based compensation expense	0.46	0.46
Acquisition related expenses (1)	0.01	0.08
Other adjustments (2)	0.94	0.15
Tax adjustments (3)	(0.08)	-
Rounding and impact of dilutive shares	-	-
Diluted EPS, non-GAAP	\$ 0.58	\$ 1.19
Diluted WASO, GAAP	72,644,487	78,163,217
Dilutive effect of equity awards (4)	1,384,916	-
Diluted WASO, non-GAAP	74,029,403	78,163,217

- Includes transaction-related expenses as well as post-combination compensation expenses. For the twelve months ended December 31, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the twelve months ended December 31, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy, post-combination compensation expenses associated with the acquisition of HalioDx and transaction related expenses associated with the acquisition of C2i Genomics.
- For the twelve months ended December 31, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment and with portfolio prioritization, expense related to Veracyte SAS site investment review, expense related to the impairment charge associated with HalioDx and the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans. For the twelve months ended December 31, 2023, adjustments primarily include \$34.9 million expense related to the impairment charge associated with the nCounter license intangible assets, \$32.0 million expense related to the impairment charge associated with HalioDx and \$1.3 million related to other impairment charges.
- Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.
- In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method.



veracyte.®